Charles Schwab Investment Management Inc Oncternal Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.7 - $1.56 $43,102 - $96,057	-61,575 Reduced 65.63%	32,249 $36,000
Q1 2022 May 13, 2022	SELL	$1.37 - $2.43 $21,718 - $38,522	-15,853 Reduced 14.45%	93,824 $131,000
Q2 2021 Aug 16, 2021	BUY	$4.75 - $9.39 $445,664 - $881,007	93,824 Added 591.84%	109,677 $521,000
Q1 2021 May 17, 2021	BUY	$4.59 - $9.04 $72,765 - $143,311	15,853 New	15,853 $132,000

362K

Ticker ONCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,517,200
Market Cap $29.4M
Description
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a smal...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.